PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 153 filers reported holding PROTAGONIST THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.62 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $230,051 | -34.0% | 13,792 | +9.4% | 0.02% | -32.0% |
| Q2 2023 | $348,343 | +10.6% | 12,612 | -7.9% | 0.02% | +8.7% |
| Q1 2023 | $314,824 | +101.1% | 13,688 | -4.6% | 0.02% | +91.7% |
| Q4 2022 | $156,559 | +21.4% | 14,350 | -6.3% | 0.01% | +20.0% |
| Q3 2022 | $129,000 | +6.6% | 15,308 | +0.2% | 0.01% | +11.1% |
| Q2 2022 | $121,000 | -99.4% | 15,274 | -98.1% | 0.01% | -99.2% |
| Q1 2022 | $18,982,000 | -29.6% | 801,625 | +1.6% | 1.14% | -21.4% |
| Q4 2021 | $26,982,000 | +96.0% | 788,942 | +1.6% | 1.44% | +89.6% |
| Q3 2021 | $13,763,000 | -59.7% | 776,689 | +2.1% | 0.76% | -59.9% |
| Q2 2021 | $34,154,000 | +241.6% | 761,018 | +97.1% | 1.90% | +208.9% |
| Q1 2021 | $9,999,000 | – | 386,072 | – | 0.62% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $19,373,000 | 4.95% |
| Bain Capital Life Sciences Investors, LLC | 2,260,572 | $17,881,000 | 2.10% |
| Finepoint Capital LP | 735,126 | $5,815,000 | 2.01% |
| Altium Capital Management LP | 365,100 | $2,888,000 | 1.16% |
| RTW INVESTMENTS, LP | 4,794,499 | $37,924,000 | 0.98% |
| Amitell Capital Pte Ltd | 50,129 | $397,000 | 0.90% |
| COWEN AND COMPANY, LLC | 1,065,724 | $8,430,000 | 0.81% |
| Tri Locum Partners LP | 155,000 | $1,226,000 | 0.50% |
| BVF INC/IL | 1,106,838 | $8,755,000 | 0.42% |
| HighVista Strategies LLC | 46,459 | $367,000 | 0.22% |